---
title: "\"Performance\" GREENHEART GP's annual loss narrowed to 100 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280041510.md"
description: "GREENHEART GP announced its performance for the year 2025, with revenue recorded at 42.36 million yuan, an increase of 8% year-on-year. The loss narrowed from 139 million yuan in the previous year to 100 million yuan, with a loss per share of 4.3 cents. No final dividend will be distributed"
datetime: "2026-03-22T05:41:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280041510.md)
  - [en](https://longbridge.com/en/news/280041510.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280041510.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/280041510.md) | [繁體中文](https://longbridge.com/zh-HK/news/280041510.md)


# "Performance" GREENHEART GP's annual loss narrowed to 100 million yuan

GREENHEART GP (00094.HK) announced its 2025 annual results, with revenue recorded at HKD 42.36 million, an increase of 8% year-on-year. The loss narrowed from HKD 139 million in the previous year to HKD 100 million, with a loss per share of HKD 0.043. No final dividend will be declared

### Related Stocks

- [GREENHEART GP (00094.HK)](https://longbridge.com/en/quote/00094.HK.md)

## Related News & Research

- [Greenheart Group Completes Sale and Announces Special Dividend](https://longbridge.com/en/news/274497649.md)
- [Greenheart Forecasts At Least 45% Narrower Loss in 2025](https://longbridge.com/en/news/277037854.md)
- [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/en/news/281325910.md)
- [China's detentions of Panama-flagged vessels raise concerns, Rubio says](https://longbridge.com/en/news/281541796.md)
- [Why Nvidia And Tesla Are Suddenly Knocking On Samsung's Door](https://longbridge.com/en/news/280999748.md)